We are live on ! Find out more
ARQT icon

Arcutis Biotherapeutics
ARQT

186 hedge funds and large institutions have $1.18B invested in Arcutis Biotherapeutics in 2024 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 59 increasing their positions, 55 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

158% more call options, than puts

Call options by funds: $7.03M | Put options by funds: $2.73M

62% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 29

11% more funds holding

Funds holding: 168 → 186 (+18)

7% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 55

0.57% more ownership

Funds ownership: 108.71% → 109.28% (+0.57%)

5% less capital invested

Capital invested by funds: $1.24B → $1.18B (-$61.9M)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
186
Holders Change
+18
Holders Change %
+10.71%
% of All Funds
2.69%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
47
Increased
59
Reduced
55
Closed
29
Calls
$7.03M
Puts
$2.73M
Net Calls
+$4.3M
Net Calls Change
+$8.98M

Top Buyers

Rank Fund Capital Flow
1
RCMNY
Rubric Capital Management (New York)
New York
+$20.9M
2
SCM
Suvretta Capital Management
New York
+$19.2M
3
BlackRock
BlackRock
New York
+$17.8M
4
CS
Candriam SCA
Luxembourg
+$11.8M
5
Citadel Advisors
Citadel Advisors
Florida
+$9.21M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$33M
2
FCM
Farallon Capital Management
California
-$15.9M
3
B
Braidwell
Connecticut
-$12.9M
4
SC
Stempoint Capital
New York
-$11.2M
5
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
-$8.87M
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS AM
51
UBS AM
Illinois
$2.55M +$2.48M +273,779 New
Rafferty Asset Management
52
Rafferty Asset Management
New York
$2.41M -$5.09M -562,983 -68%
AQR Capital Management
53
AQR Capital Management
Connecticut
$2.39M +$2.05M +226,258 +728%
Schroder Investment Management Group
54
Schroder Investment Management Group
United Kingdom
$2.06M +$1.84M +203,562 +1,122%
Swiss National Bank
55
Swiss National Bank
Switzerland
$1.89M +$1.84M +203,600 New
Adage Capital Partners
56
Adage Capital Partners
Massachusetts
$1.86M +$1.81M +200,000 New
Jacobs Levy Equity Management
57
Jacobs Levy Equity Management
New Jersey
$1.64M +$1.59M +175,909 New
Norges Bank
58
Norges Bank
Norway
$1.63M – – –
PI
59
Pennant Investors
New Jersey
$1.59M – – –
RhumbLine Advisers
60
RhumbLine Advisers
Massachusetts
$1.56M +$379K +41,956 +33%
AAM
61
AMI Asset Management
California
$1.53M -$1.64M -181,045 -52%
EIM
62
Essex Investment Management
Massachusetts
$1.52M +$1.48M +163,561 New
Acadian Asset Management
63
Acadian Asset Management
Massachusetts
$1.49M +$1.45M +160,028 New
SCM
64
Sio Capital Management
New York
$1.48M -$4.31M -476,343 -75%
JF
65
Jump Financial
Illinois
$1.41M +$758K +83,787 +124%
Jane Street
66
Jane Street
New York
$1.4M -$574K -63,431 -30%
LPL Financial
67
LPL Financial
California
$1.39M -$78.4K -8,665 -5%
Aberdeen Group
68
Aberdeen Group
United Kingdom
$1.38M – – –
DekaBank Deutsche Girozentrale
69
DekaBank Deutsche Girozentrale
Germany
$1.34M – – –
BFM
70
Boothbay Fund Management
New York
$1.33M -$263K -29,135 -17%
Fidelity Investments
71
Fidelity Investments
Massachusetts
$1.27M -$43.1K -4,763 -3%
Los Angeles Capital Management
72
Los Angeles Capital Management
California
$1.26M -$113K -12,485 -8%
JSSH
73
J. Safra Sarasin Holding
$1.2M +$1.17M +129,560 New
AllianceBernstein
74
AllianceBernstein
Tennessee
$1.03M +$330K +36,460 +49%
Legal & General Group
75
Legal & General Group
United Kingdom
$971K +$869K +96,075 +1,155%
1 2
3
4 5

ARQT Hedge Fund Activity: Q2 2024 in Review

186 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q2 2024, worth a combined $1.18B — down 5% from $1.24B a quarter earlier.

Buyers outnumbered sellers: 47 funds opened new ARQT positions and 29 closed out — a net gain of 18 holders — while 59 added to existing stakes and 55 trimmed.

The largest buyer was Rubric Capital Management (New York), adding an estimated $20.9M. The largest seller was State Street, cutting an estimated $33M.

  • 186 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q2 2024, up from 168 in Q1 2024.
  • Funds reported $1.18B of Arcutis Biotherapeutics stock for Q2 2024, down 5% quarter-over-quarter.
  • 47 funds opened new Arcutis Biotherapeutics positions in Q2 2024 and 29 closed out, a net change of +18 holders.
  • The largest Arcutis Biotherapeutics buyer in Q2 2024 was Rubric Capital Management (New York), an estimated $20.9M added.
  • The largest Arcutis Biotherapeutics seller in Q2 2024 was State Street, an estimated $33M sold.

Based on aggregated 13F filings for Q2 2024.